Related Experiment Video

Updated: May 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[Mechanisms of resistance to BCR-ABL kinase inhibitors]

Joana Diamond1, Maria Gomes da Silva

  • 1Laboratório de Hemato-Oncologia. Unidade de Biologia Molecular. Instituto Português de Oncologia Francisco Gentil. Lisboa. Portugal.. jdiamond@ipolisboa.min-saude.pt.

Acta Medica Portuguesa
|September 11, 2013
PubMed

Insights

Second-generation tyrosine kinase inhibitors (TKIs) are effective for chronic myeloid leukaemia, but resistance remains a challenge. This review explores the mechanisms behind TKI resistance in chronic myeloid leukaemia.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Context:

  • Imatinib mesylate revolutionized chronic myeloid leukaemia (CML) treatment, achieving high response rates in chronic phase.
  • Despite initial success, not all patients achieve optimal responses or sustained remission with imatinib or newer generation TKIs.
  • The long-term safety of discontinuing TKIs in patients with deep remission is still under investigation.

Purpose:

  • To review the current understanding of resistance mechanisms to second-generation tyrosine kinase inhibitors in chronic myeloid leukaemia.
  • To elucidate the molecular pathways and cellular processes that lead to treatment failure.

Summary:

  • While first- and second-generation tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukaemia (CML) therapy, acquired resistance remains a significant clinical hurdle.
  • This review details the known mechanisms by which CML cells develop resistance to potent second-generation TKIs.
  • Understanding these resistance pathways is crucial for developing strategies to overcome treatment failure.

Impact:

  • Provides a comprehensive overview of TKI resistance in CML for researchers and clinicians.
  • Highlights the need for further investigation into overcoming resistance to improve long-term CML management.
  • Informs the development of novel therapeutic strategies for patients resistant to current TKI treatments.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...